• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Editorial overview: Anti-viral strategies: Human antibody immune response and antibody-based therapy against viruses.

作者信息

Wang Qiao, Huang Zhong

机构信息

Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, China.

Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China.

出版信息

Curr Opin Virol. 2022 Aug;55:101247. doi: 10.1016/j.coviro.2022.101247. Epub 2022 Jul 6.

DOI:10.1016/j.coviro.2022.101247
PMID:35803202
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9256202/
Abstract
摘要

相似文献

1
Editorial overview: Anti-viral strategies: Human antibody immune response and antibody-based therapy against viruses.社论综述：抗病毒策略：人类抗体免疫反应及基于抗体的病毒治疗
Curr Opin Virol. 2022 Aug;55:101247. doi: 10.1016/j.coviro.2022.101247. Epub 2022 Jul 6.
2
Fcγ Receptors Contribute to the Antiviral Properties of Influenza Virus Neuraminidase-Specific Antibodies.Fcγ 受体有助于流感病毒神经氨酸酶特异性抗体的抗病毒特性。
mBio. 2019 Oct 22;10(5):e01667-19. doi: 10.1128/mBio.01667-19.
3
Antiviral Monoclonal Antibodies: Can They Be More Than Simple Neutralizing Agents?抗病毒单克隆抗体：它们能否不仅仅是简单的中和剂？
Trends Microbiol. 2015 Oct;23(10):653-665. doi: 10.1016/j.tim.2015.07.005.
4
A Novel Mechanism Underlying Antiviral Activity of an Influenza Virus M2-Specific Antibody.一种新型机制：流感病毒 M2 特异性抗体的抗病毒活性。
J Virol. 2020 Dec 9;95(1). doi: 10.1128/JVI.01277-20.
5
Innate antiviral immune signaling, viral evasion and modulation by HIV-1.先天抗病毒免疫信号、HIV-1 的病毒逃逸和调节。
J Mol Biol. 2014 Mar 20;426(6):1161-77. doi: 10.1016/j.jmb.2013.12.003. Epub 2013 Dec 8.
6
T-bodies as antiviral agents.
Curr Top Microbiol Immunol. 2001;260:271-300. doi: 10.1007/978-3-662-05783-4_14.
7
Serum strain-specific or cross-reactive neuraminidase inhibiting antibodies against pandemic А/California/07/2009(H1N1) influenza in healthy volunteers.健康志愿者体内针对大流行的A/加利福尼亚/07/2009（H1N1）流感病毒的血清型特异性或交叉反应性神经氨酸酶抑制抗体。
BMC Res Notes. 2015 Apr 10;8:136. doi: 10.1186/s13104-015-1086-z.
8
Human Monoclonal Antibody 81.39a Effectively Neutralizes Emerging Influenza A Viruses of Group 1 and 2 Hemagglutinins.人源单克隆抗体81.39a可有效中和1组和2组血凝素的新型甲型流感病毒。
J Virol. 2016 Nov 14;90(23):10446-10458. doi: 10.1128/JVI.01284-16. Print 2016 Dec 1.
9
Human β-defensin 2 plays a regulatory role in innate antiviral immunity and is capable of potentiating the induction of antigen-specific immunity.人 β-防御素 2 在先天抗病毒免疫中发挥调节作用，并能够增强抗原特异性免疫的诱导。
Virol J. 2018 Aug 8;15(1):124. doi: 10.1186/s12985-018-1035-2.
10
[Antiviral humanized and human monoclonal antibodies].[抗病毒人源化单克隆抗体及人单克隆抗体]
Vopr Virusol. 2011 Sep-Oct;56(5):4-8.

引用本文的文献

1
Latest developments in early diagnosis and specific treatment of severe influenza infection.重症流感感染早期诊断与特异性治疗的最新进展
J Intensive Med. 2023 Dec 19;4(2):160-174. doi: 10.1016/j.jointm.2023.09.006. eCollection 2024 Apr.

本文引用的文献

1
Broadly neutralizing antibodies against HIV-1 and concepts for application.广谱中和抗体抗 HIV-1 及应用概念。
Curr Opin Virol. 2022 Jun;54:101211. doi: 10.1016/j.coviro.2022.101211. Epub 2022 Mar 17.
2
The road to effective and accessible antibody therapies against Ebola virus.对抗埃博拉病毒的有效且可及的抗体疗法之路。
Curr Opin Virol. 2022 Jun;54:101210. doi: 10.1016/j.coviro.2022.101210. Epub 2022 Mar 11.
3
Monoclonal antibodies against rabies: current uses in prophylaxis and in therapy.抗狂犬病单克隆抗体：目前在预防和治疗中的应用
Curr Opin Virol. 2022 Apr;53:101204. doi: 10.1016/j.coviro.2022.101204. Epub 2022 Feb 10.
4
Broad neutralizing antibody-based strategies to tackle influenza.基于广泛中和抗体的流感应对策略。
Curr Opin Virol. 2022 Apr;53:101207. doi: 10.1016/j.coviro.2022.101207. Epub 2022 Feb 5.
5
Advances in human monoclonal antibody therapy for HBV infection.HBV 感染的人源单克隆抗体治疗进展。
Curr Opin Virol. 2022 Apr;53:101205. doi: 10.1016/j.coviro.2022.101205. Epub 2022 Feb 2.
6
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans.SARS-CoV-2 单克隆抗体组合药物 AZD7442 在非人类灵长类动物中具有保护作用，在人体内半衰期延长。
Sci Transl Med. 2022 Mar 9;14(635):eabl8124. doi: 10.1126/scitranslmed.abl8124.
7
Neutralizing monoclonal antibodies against highly pathogenic coronaviruses.针对高致病性冠状病毒的中和单克隆抗体。
Curr Opin Virol. 2022 Apr;53:101199. doi: 10.1016/j.coviro.2021.12.015. Epub 2021 Dec 30.
8
Recent progress in development of monoclonal antibodies against human cytomegalovirus.抗人巨细胞病毒单克隆抗体研发的最新进展
Curr Opin Virol. 2022 Feb;52:166-173. doi: 10.1016/j.coviro.2021.12.002. Epub 2021 Dec 21.
9
Development of plant-made monoclonal antibodies against viral infections.植物源性单克隆抗体抗病毒感染的研究进展。
Curr Opin Virol. 2022 Feb;52:148-160. doi: 10.1016/j.coviro.2021.12.005. Epub 2021 Dec 18.
10
Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy.具有提高的抗SARS-CoV-2疗效的Fc工程化抗体疗法。
Nature. 2021 Nov;599(7885):465-470. doi: 10.1038/s41586-021-04017-w. Epub 2021 Sep 21.